Autoinflammatory Diseases in Childhood

ANDROVIC, Amra; YILDIZ, Mehmet Zülfü; BARUT, Kenan; Kasapcopur, Ozgur; HAŞLAK, Fatih

doi:10.4274/balkanmedj.galenos.2020.2020.4.82

Autoinflammatory Diseases in Childhood

Mehmet Zülfü YILDIZ, (Girilmemişş)

Fatih HAŞLAK, (Girilmemişş)

Amra ANDROVIC, (Girilmemişş)

Kenan BARUT, (Girilmemişş)

Özgür KASAPÇOPUR (Girilmemişş)

Balkan Medical Journal

1 0

Yıl: 2020 Cilt: 37 Sayı: 5 Sayfa Aralığı: 236 - 246 Metin Dili: İngilizce DOI: 10.4274/balkanmedj.galenos.2020.2020.4.82 İndeks Tarihi: 27-11-2020

Autoinflammatory Diseases in Childhood

Öz:

Autoinflammatory diseases are characterized by recurrent feversand clinical findings of impaired natural immunity and can involvevarious organ systems. The concept of autoinflammatory diseaseemerged after the definition of familial Mediterranean fever andtumor necrosis factor receptor-associated periodic syndrome. Thisnew disease group was considered to differ from the standard conceptof autoimmune diseases, which is relatively better known in terms ofbasic features, such as defects in innate immunity and the absence ofantibodies. A better understanding has been achieved regarding thegenetic and pathogenetic mechanisms of this relatively new diseasegroup over the past 20 years since they were first diagnosed, whichhave led to some changes in the concept of autoinflammatory diseases.The recent definition classifies autoinflammatory disease to be a widerange of diseases with different clinical features, mainly accompaniedby changes in innate immune and rarely in humoral immunity. Thespectrum of autoinflammatory diseases is rapidly expanding owing torecent developments in molecular sciences and genetics. This reviewarticle discusses the clinical features, classification criteria, treatmentoptions, and long-term prognosis of periodic fever, aphthous stomatitis,pharyngitis, adenitis syndrome, and other common autoinflammatorydiseases in the light of current literature.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Ben-Chetrit E, Gattorno M, Gul A, Kastner DL, Lachmann HJ, Touitou I, et al. Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study. Ann Rheum Dis 2018;77:1558-65.
2. McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999;97:133-44.
3. Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell 2010;140:784-90.
4. Wekell P, Berg S, Karlsson A, Fasth A. Toward an Inclusive, Congruent, and Precise Definition of Autoinflammatory Diseases. Front Immunol 2017;8:497.
5. Adrovic A, Sahin S, Barut K, Kasapcopur O. Familial Mediterranean fever and periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome: shared features and main differences. Rheumatol Int 2019;39:29-36.
6. Sag E, Bilginer Y, Ozen S. Autoinflammatory Diseases with Periodic Fevers. Curr Rheumatol Rep 2017;19:41.
7. Di Gioia SA, Bedoni N, von Scheven-Gete A, Vanoni F, Superti-Furga A, Hofer M, et al. Analysis of the genetic basis of periodic fever with aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome. Sci Rep 2015;5:10200.
8. Butbul Aviel Y, Harel L, Abu Rumi M, Brik R, Hezkelo N, Ohana O, et al. Familial Mediterranean Fever Is Commonly Diagnosed in Children in Israel with Periodic Fever Aphthous Stomatitis, Pharyngitis, and Adenitis Syndrome. J Pediatr 2019;204:270-4.
9. Manthiram K, Nesbitt E, Morgan T, Edwards KM. Family History in Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis (PFAPA) Syndrome. Pediatrics 2016;138:e20154572.
10. Vigo G, Martini G, Zoppi S, Vittadello F, Zulian F. Tonsillectomy efficacy in children with PFAPA syndrome is comparable to the standard medical treatment: a long-term observational study. Clin Exp Rheumatol 2014;32(4 Suppl 84):156-9.
11. Batu ED. Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome: main features and an algorithm for clinical practice. Rheumatol Int 2019;39:957-70.
12. Gattorno M, Caorsi R, Meini A, Cattalini M, Federici S, Zulian F, et al. Differentiating PFAPA Syndrome From Monogenic Periodic Fevers. Pediatrics 2009;124:721-8.
13. Batu ED, Kara Eroğlu F, Tsoukas P, Hausmann JS, Bilginer Y, Kenna MA, et al. Periodic Fever, Aphthosis, Pharyngitis, and Adenitis Syndrome: Analysis of Patients From Two Geographic Areas. Arthritis Care Res (Hoboken) 2016;68:1859-65.
14. Gunes M, Cekic S, Kilic SS. Is colchicine more effective to prevent periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis episodes in Mediterranean fever gene variants? Pediatr Int 2017;59:655-60.
15. Pehlivan E, Adrovic A, Sahin S, Barut K, Kul Cınar O, Kasapcopur O. PFAPA Syndrome in a Population with Endemic Familial Mediterranean Fever. J Pediatr 2018;192:253-5.
16. Perko D, Debeljak M, Toplak N, Avčin T. Clinical features and genetic background of the periodic Fever syndrome with aphthous stomatitis, pharyngitis, and adenitis: a single center longitudinal study of 81 patients. Mediators Inflamm 2015;2015:293417.
17. Berkun Y, Levy R, Hurwitz A, Meir-Harel M, Lidar M, Livneh A, et al. The familial Mediterranean fever gene as a modifier of periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome. Semin Arthritis Rheum 2011;40:467-72.
18. Taniuchi S, Nishikomori R, Iharada A, Tuji S, Heike T, Kaneko K. MEFV Variants in Patients with PFAPA Syndrome in Japan. Open Rheumatol J 2013;7:22-5.
19. Thomas KT, Feder HM Jr, Lawton AR, Edwards KM. Periodic fever syndrome in children. J Pediatr 1999;135:15-21.
20. Vanoni F, Caorsi R, Aeby S, Cochard M, Antón J, Berg S, et al. Towards a new set of classification criteria for PFAPA syndrome. Pediatr Rheumatol Online J 2018;16:60.
21. Adrovic A, Yıldız M, Kanber M, Ulkersoy I, Gucuyener N, Koker O, et al. Performance of recently proposed periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome criteria in a region endemic for familial Mediterranean fever. Rheumatol Int 2020;40:91-6.
22. Gattorno M, Hofer M, Federici S, Vanoni F, Bovis F, Aksentijevich I, et al. Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis 2019;78:1025-32.
23. Vanoni F, Theodoropoulou K, Hofer M. PFAPA syndrome: a review on treatment and outcome. Pediatr Rheumatol Online J 2016;14:38.
24. Ozdogan H, Ugurlu S. Familial Mediterranean Fever. Presse Med 2019;48:61-76.
25. Ozen S, Bilginer Y. A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol 2014;10:135-47.
26. Ben-Chetrit E, Touitou I. Familial Mediterranean Fever in the World. Arthritis Rheum 2009;61:1447-53.
27. French FMFC. A candidate gene for familial Mediterranean fever. Nat Genet 1997;17:25-31.
28. Booth DR, Gillmore JD, Lachmann HJ, Booth SE, Bybee A, Soytürk M, et al. The genetic basis of autosomal dominant familial Mediterranean fever. QJM 2000;93:217-21.
29. Milhavet F, Cuisset L, Hoffman HM, Slim R, El-Shanti H, Aksentijevich I, et al. The infevers autoinflammatory mutation online registry: update with new genes and functions. Hum Mutat 2008;29:803-8.30. Ben-Zvi I, Herskovizh C, Kukuy O, Kassel Y, Grossman C, Livneh A. Familial Mediterranean fever without MEFV mutations: a case-control study. Orphanet J Rare Dis 2015;10:34.
31. Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever: A survey of 470 cases and review of the literature. Am J Med 1967;43:227-53.
32. Lidar M, Yaqubov M, Zaks N, Ben-Horin S, Langevitz P, Livneh A. The prodrome: a prominent yet overlooked pre-attack manifestation of familial Mediterranean fever. J Rheumatol 2006;33:1089-92.
33. Barut K, Sahin S, Adrovic A, Sinoplu AB, Yucel G, Pamuk G, et al. Familial Mediterranean fever in childhood: a single-center experience. Rheumatol Int 2018;38:67-74.
34. Lachmann HJ. Periodic fever syndromes. Best Pract Res Clin Rheumatol 2017;31:596- 609.
35. Ozer E, Seker D, Taner E, Adrovic A, Sahin S, Barut K, et al. The frequency of juvenile spondyloarthropathies in childhood familial Mediterranean fever. Clin Exp Rheumatol 2018;36(6 Suppl 115):141-5.
36. Kaplan E, Mukamel M, Barash J, Brik R, Padeh S, Berkun Y, et al. Protracted febrile myalgia in children and young adults with familial Mediterranean fever: analysis of 15 patients and suggested criteria for working diagnosis. Clin Exp Rheumatol 2007;25(4 Suppl 45):114-7.
37. Barut K, Guler M, Sezen M, Kasapçopur O. Inceased frequency of psoriasis in the families of the children with familial Mediterranean fever. Clin Exp Rheumatol 2016;34(6 Suppl 102):137.
38. Yildiz M, Adrovic A, Tasdemir E, Baba-Zada K, Aydin M, Koker O, et al. Evaluation of co-existing diseases in children with familial Mediterranean fever. Rheumatol Int 2020;40:57-64.
39. Yalçinkaya F, Ozen S, Ozçakar ZB, Aktay N, Cakar N, Düzova A, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford) 2009;48:395-8.
40. Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997;40:1879-85.
41. Sag E, Demirel D, Demir S, Atalay E, Akca U, Bilginer Y, et al. Performance of the new ‘Eurofever/PRINTO classification criteria’ in FMF patients. Semin Arthritis Rheum 2020;50:172-5.
42. Ozkan E, Okur O, Ekmekci A, Ozcan R, Tag T. A new approach to the treatment of periodic fever. Med Bull Istanbul. 1972;5:44-9.
43. Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med 1972;287:1302.
44. Hentgen V, Grateau G, Kone-Paut I, Livneh A, Padeh S, Rozenbaum M, et al. Evidence-based recommendations for the practical management of Familial Mediterranean Fever. Semin Arthritis Rheum 2013;43:387-91.
45. Emmungil H, İlgen U, Turan S, Yaman S, Küçükşahin O. Different pharmaceutical preparations of colchicine for Familial Mediterranean Fever: are they the same? Rheumatol Int 2020;40:129-35.
46. De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med 2018;378:1908-19.
47. Ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis 2015;74:1636-44.
48. Ammouri W, Cuisset L, Rouaghe S, Rolland M-O, Delpech M, Grateau G, et al. Diagnostic value of serum immunoglobulinaemia D level in patients with a clinical suspicion of hyper IgD syndrome. Rheumatology (Oxford) 2007;46:1597-600.
49. Pepper RJ, Lachmann HJ. Autoinflammatory syndromes in children. Indian J Pediatr 2016;83:242-7.
50. Drenth JP, Cuisset L, Grateau G, Vasseur C, van de Velde-Visser SD, de Jong JG, et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. Nat Genet 1999;22:178-81.
51. Simon A, van der Meer JW. Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. Am J Physiol Regul Integr Comp Physiol 2007;292:86-98.
52. Dueckers G, Sander O, Niehues T. Autoinflammatory diseases (AID). Klin Pädiatr 2014;226:133-42.
53. Rigante D, Frediani B, Cantarini L. A comprehensive overview of the hereditary periodic fever syndromes. Clin Rev Allergy Immunol 2018;54:446-53.
54. Tripathi SV, Leslie KS. Autoinflammatory Diseases in Dermatology: CAPS, TRAPS, HIDS, FMF, Blau, CANDLE. Dermatol Clin 2013;31:387-404.
55. Drenth JP, Van Der Meer JW. Hereditary periodic fever. N Engl J Med 2001;345:1748-57.
56. Havnaer A, Han G. Autoinflammatory disorders: a review and update on pathogenesis and treatment. Am J Clin Dermatol 2019;20:539-64.
57. Hoffmann GF, Charpentier C, Mayatepek E, Mancini J, Leichsenring M, Gibson KM, et al. Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics 1993;91:915-21.
58. van der Hilst JC, Bodar EJ, Barron KS, Frenkel J, Drenth JP, van der Meer JW, et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) 2008;87:301-10.
59. Rigante D, Ansuini V, Bertoni B, Pugliese AL, Avallone L, Federico G, et al. Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome. Rheumatol Int 2006;27:97-100.
60. Takada K, Aksentijevich I, Mahadevan V, Dean JA, Kelley RI, Kastner DL. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2003;48:2645-51.
61. Cantarini L, Lucherini OM, Muscari I, Frediani B, Galeazzi M, Brizi MG, et al. Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. Autoimmun Rev 2012;12:38-43.
62. Rigante D, Lopalco G, Vitale A, Lucherini OM, De Clemente C, Caso F, et al. Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome. Clin Rheumatol 2014;33:1197-207.
63. Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, Oh HH, et al. The tumornecrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Gen 2001;69:301-14.
64. Mulley J, Saar K, Hewitt G, Rüschendorf F, Phillips H, Colley A, et al. Gene localization for an autosomal dominant familial periodic fever to 12p13. Am J Hum Gene 1998;62:884-9.
65. McDermott MF, Ogunkolade BW, McDermott EM, Jones LC, Wan Y, Quane KA, et al. Linkage of familial Hibernian fever to chromosome 12p13. American J Hum Genet 1998;62:1446-51.
66. Ravet N, Rouaghe S, Dodé C, Bienvenu J, Stirnemann J, Lévy P, et al. Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Ann Rheum Dis 2006;65:1158-62.
67. Aksentijevich I, Kastner DL. Genetics of monogenic autoinflammatory diseases: past successes, future challenges. Nat Rev Rheumatol 2011;7:469-78.
68. Stojanov S, McDermott MF. The tumour necrosis factor receptor-associated periodic syndrome: current concepts. Expert Rev Mol Med 2005;7:1-18.
69. Toro JR, Aksentijevich I, Hull K, Dean J, Kastner DL. Tumor necrosis factor receptorassociated periodic syndrome: a novel syndrome with cutaneous manifestations. Arch Dermatol 2000;136:1487-94.
70. Cantarini L, Lucherini OM, Cimaz R, Brizi MG, Galeazzi M. Serosal involvement in adult-onset autoinflammatory disorders. Respiration 2010;80:260-2.
71. Cantarini L, Lucherini OM, Cimaz R, Galeazzi M. Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment. Clin Exp Rheumatol 2010;28:802.
72. Dodé C, André M, Bienvenu T, Hausfater P, Pêcheux C, Bienvenu J, et al. The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptorassociated periodic syndrome. Arthritis Rheum 2002;46:2181-8.
73. Cantarini L, Lucherini OM, Cimaz R, Baldari CT, Laghi Pasini F, Galeazzi M. Sacroileitis and pericarditis: atypical presentation of tumor necrosis factor receptorassociated periodic syndrome and response to etanercept therapy. Clin Exp Rheumatol 2010;28:290-1.
74. Trost S, Rosé CD. Myocarditis and sacroiliitis: 2 previously unrecognized manifestations of tumor necrosis factor receptor associated periodic syndrome. J Rheumatol 2005;32:175-7.
75. Obici L, Merlini G. Amyloidosis in autoinflammatory syndromes. Autoimmunity Rev 2012;12:14-7.
76. Ter Haar N, Lachmann H, Özen S, Woo P, Uziel Y, Modesto C, et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2013;72:678-85.
77. Cantarini L, Lucherini OM, Galeazzi M, Fanti F, Simonini G, Baldari CT, et al. Tumour necrosis factor receptor-associated periodic syndrome caused by a rare mutation in the TNFRSF1A gene, and with excellent response to etanercept treatment. Clin Exp Rheumatol 2009;27:890-1.
78. Gattorno M, Pelagatti MA, Meini A, Obici L, Barcellona R, Federici S, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008;58:1516-20.
79. De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med 2018;378:1908-19.
80. Booshehri LM, Hoffman HM. CAPS and NLRP3. J Clin Immunol 2019;39:277-86.
81. Aksentijevich I, Putnam CD, Remmers EF, Mueller JL, Le J, Kolodner RD, et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007;56:1273-85.
82. Kuemmerle-Deschner JB. CAPS--pathogenesis, presentation and treatment of an autoinflammatory disease. Semin Immunopathol 2015;37:377-85.
83. Kastner DL. Hereditary periodic fever syndromes. Hematology Am Soc Hematol Educ Program 2005:74-81.
84. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001;29:301-5.
85. Dollfus H, Häfner R, Hofmann HM, Russo RA, Denda L, Gonzales LD, et al. Chronic infantile neurological cutaneous and articular/neonatal onset multisystem inflammatory disease syndrome: ocular manifestations in a recently recognized chronic inflammatory disease of childhood. Arch Ophthalmol 2000;118:1386-92.
86. Alejandre N, Ruiz-Palacios A, García-Aparicio AM, Blanco-Kelly F, Bermúdez S, Fernández-Sanz G, et al. Description of a new family with cryopyrin-associated periodic syndrome: risk of visual loss in patients bearing the R260W mutation. Rheumatology (Oxford) 2014;53:1095-9.
87. Kilic H, Sahin S, Duman C, Adrovic A, Barut K, Turanli ET, et al. Spectrum of the neurologic manifestations in childhood-onset cryopyrin-associated periodic syndrome. Eur J Paediat Neurol 2019;23:466-72.
88. Tanaka N, Izawa K, Saito MK, Sakuma M, Oshima K, Ohara O, et al. High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: Results of an international multicenter collaborative study. Arthritis Rheum 2011;63:3625-32.
89. Eroglu FK, Kasapcopur O, Beşbaş N, Ozaltin F, Bilginer Y, Barut K, et al. Genetic and clinical features of cryopyrin-associated periodic syndromes in Turkish children. Clin Exp Rheumatol 2016;34(6 Suppl 102):115-20.
90. Kuemmerle-Deschner JB, Ozen S, Tyrrell PN, Kone-Paut I, Goldbach-Mansky R, Lachmann H, et al. Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Ann Rheum Dis 2017;76:942-7.
91. Leslie KS, Lachmann HJ, Bruning E, McGrath JA, Bybee A, Gallimore JR, et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 2006;142:1591-7.
92. Ross JB, Finlayson LA, Klotz PJ, Langley RG, Gaudet R, Thompson K, et al. Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J Cutan Med Surg 2008;12:8-16.
93. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008;58:2443-52.
94. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009;360:2416-25.
95. Karacan İ, BalamirA, Uğurlu S,AydınAK, Everest E, Zor S, et al. Diagnostic utility of a targeted next-generation sequencing gene panel in the clinical suspicion of systemic autoinflammatory diseases: a multi-center study. Rheumatology Int 2019;39:911-9.

APA	YILDIZ M, HAŞLAK F, ANDROVIC A, BARUT K, Kasapcopur O (2020). Autoinflammatory Diseases in Childhood. , 236 - 246. 10.4274/balkanmedj.galenos.2020.2020.4.82
Chicago	YILDIZ Mehmet Zülfü,HAŞLAK Fatih,ANDROVIC Amra,BARUT Kenan,Kasapcopur Ozgur Autoinflammatory Diseases in Childhood. (2020): 236 - 246. 10.4274/balkanmedj.galenos.2020.2020.4.82
MLA	YILDIZ Mehmet Zülfü,HAŞLAK Fatih,ANDROVIC Amra,BARUT Kenan,Kasapcopur Ozgur Autoinflammatory Diseases in Childhood. , 2020, ss.236 - 246. 10.4274/balkanmedj.galenos.2020.2020.4.82
AMA	YILDIZ M,HAŞLAK F,ANDROVIC A,BARUT K,Kasapcopur O Autoinflammatory Diseases in Childhood. . 2020; 236 - 246. 10.4274/balkanmedj.galenos.2020.2020.4.82
Vancouver	YILDIZ M,HAŞLAK F,ANDROVIC A,BARUT K,Kasapcopur O Autoinflammatory Diseases in Childhood. . 2020; 236 - 246. 10.4274/balkanmedj.galenos.2020.2020.4.82
IEEE	YILDIZ M,HAŞLAK F,ANDROVIC A,BARUT K,Kasapcopur O "Autoinflammatory Diseases in Childhood." , ss.236 - 246, 2020. 10.4274/balkanmedj.galenos.2020.2020.4.82
ISNAD	YILDIZ, Mehmet Zülfü vd. "Autoinflammatory Diseases in Childhood". (2020), 236-246. https://doi.org/10.4274/balkanmedj.galenos.2020.2020.4.82

APA	YILDIZ M, HAŞLAK F, ANDROVIC A, BARUT K, Kasapcopur O (2020). Autoinflammatory Diseases in Childhood. Balkan Medical Journal, 37(5), 236 - 246. 10.4274/balkanmedj.galenos.2020.2020.4.82
Chicago	YILDIZ Mehmet Zülfü,HAŞLAK Fatih,ANDROVIC Amra,BARUT Kenan,Kasapcopur Ozgur Autoinflammatory Diseases in Childhood. Balkan Medical Journal 37, no.5 (2020): 236 - 246. 10.4274/balkanmedj.galenos.2020.2020.4.82
MLA	YILDIZ Mehmet Zülfü,HAŞLAK Fatih,ANDROVIC Amra,BARUT Kenan,Kasapcopur Ozgur Autoinflammatory Diseases in Childhood. Balkan Medical Journal, vol.37, no.5, 2020, ss.236 - 246. 10.4274/balkanmedj.galenos.2020.2020.4.82
AMA	YILDIZ M,HAŞLAK F,ANDROVIC A,BARUT K,Kasapcopur O Autoinflammatory Diseases in Childhood. Balkan Medical Journal. 2020; 37(5): 236 - 246. 10.4274/balkanmedj.galenos.2020.2020.4.82
Vancouver	YILDIZ M,HAŞLAK F,ANDROVIC A,BARUT K,Kasapcopur O Autoinflammatory Diseases in Childhood. Balkan Medical Journal. 2020; 37(5): 236 - 246. 10.4274/balkanmedj.galenos.2020.2020.4.82
IEEE	YILDIZ M,HAŞLAK F,ANDROVIC A,BARUT K,Kasapcopur O "Autoinflammatory Diseases in Childhood." Balkan Medical Journal, 37, ss.236 - 246, 2020. 10.4274/balkanmedj.galenos.2020.2020.4.82
ISNAD	YILDIZ, Mehmet Zülfü vd. "Autoinflammatory Diseases in Childhood". Balkan Medical Journal 37/5 (2020), 236-246. https://doi.org/10.4274/balkanmedj.galenos.2020.2020.4.82